Frailty is defined as a syndrome of physiological decline in late life, characterised by marked vulnerability to adverse health outcomes. A robust biomarker for frailty is still lacking. Tryptophan (TRP) metabolism through the kynurenine pathway (KP) plays essential roles in aging, the musculoskeletal system and physical performance. In this study, we quantified seven KP metabolites, including kynurenine (KYN), kynurenine acid (KYNA), quinolinic acid (QUIN), picolinic acid (PIC), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA) and anthranilic acid (AA) using ultra-high-performance liquid chromatography and gas chromatography-mass spectrometry in the serum of 85 participants (median age 75; 65% female; 28 non-frail, 29 pre-frail, and 28 frail) at the Nepean Osteoporosis and Frailty (NOF) Study. We looked at the association between TRP metabolites and physical performance, sarcopenia, and frailty.
After adjusting for age and sex, our results showed that KYN and KYN/TRP were associated with higher IL6 levels (r=0.324 and r=0.390, respectively). KYNA and its ratios to other products (mainly KYNA/KYN, KYNA/QUIN and KYNA/PIC) were associated with lower likelihood of frailty by Fried’s criteria (OR 0.93 [0.88, 0.98], p=0.009) and Rockwood index (r=-0.241, p=0.028) as well as lower likelihood of sarcopenia (OR 0.88 [0.78, 1.00], p=0.049). QUIN and QUIN/KYN showed an association with increased IL-6 (r=0.293 and 0.204 respectively), higher likelihood of frailty (OR 1.02 [1.00, 1.04], p=0.029 and OR 6.43 [2.23, 18.51], p=0.001 respectively) and lower physical function (r=-0.205 and r=-0.292).
In conclusion, different TRP metabolites have various associations with physical performance, frailty and sarcopenia. Defining the underlying mechanisms may permit the development and validation of new biomarkers and therapeutics for frailty and musculoskeletal conditions targeting specific metabolites of the TRP catabolic pathway